Sophia Genetics SA (SOPH) News
Filter SOPH News Items
SOPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SOPH News Highlights
- For SOPH, its 30 day story count is now at 8.
- Over the past 29 days, the trend for SOPH's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- NGS, SA and DE are the most mentioned tickers in articles about SOPH.
Latest SOPH News From Around the Web
Below are the latest news stories about SOPHiA GENETICS SA that investors may wish to consider to help them evaluate SOPH as an investment opportunity.
SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination DeficienciesSOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. |
First Japanese Institution to Utilize SOPHiA GENETICS'' Myeloid Plus SolutionBOSTON , LAUSANNE, Switzerland , and HIROSHIMA, Japan , Feb. 22, 2022 /CNW/ -- SOPHiA GENETICS (NASDAQ: SOPH ), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan , to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders. Hiroshima University is home to one of the largest university research institutes in the field of radiation biomedical science in Japan. With NGS for myeloid testing not widely available in Japan , a group of Hiroshima University researchers tapped the SOPHiA DDM Platform to assist with the clinical utility of NGS tests for myeloid malignancies. Hiroshima University aimed to establish a framework where the N... |
First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus SolutionSOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan, to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders. |
SOPHiA GENETICS to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022BOSTON and LAUSANNE, Switzerland, Feb. 16, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2021 before U.S. markets open on Tuesday, March 15, 2022. SOPHiA will host a conference call and live webcast to discuss its financial results as well as business outlook beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time. |
SOPHiA GENETICS (NASDAQ:SOPH) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Institut Paoli Calmettes Extends Partnership with SOPHiA GENETICSSOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, have announced, in conjunction with Assises de Génétique, an extension of their partnership with Institut Paoli Calmettes (IPC), one of the 18 French Cancer Comprehensive Centers (CLCC), to further support the implementation, automatization, and accreditation of solid tumor tests, to include lung, breast, ovarian and onco-hematological cancers. |
SOPHiA GENETICS Appoints Ken Freedman as Chief Revenue OfficerSOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that democratizes data-driven medicine, today announced that Ken Freedman has been appointed Chief Revenue Officer. With a background in serving some of the most innovative providers of technology to the world-wide media space, Ken brings more than 25 years of sales, marketing, and executive management experience. |
SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical StudySOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT04994795). Since officially launching last month, 12 sites across 5 countries have already signed up for participation in the study. |
Executive Team Hires at SOPHiA GENETICS to Enhance BioPharma BusinessSOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced key additions to their leadership team with the hiring of Peter Casasanto as Chief BioPharma Officer and Abhimanyu (Abhi) Verma as Chief Technology Officer. The additions are part of SOPHiA GENETICS' strategy to enhance its business in the pharmaceutical industry. Peter and Abhi will help the company drive deeper with a focus on leveraging data for |
SOPHiA GENETICS to Present at the 40th Annual J.P. Morgan Healthcare ConferenceBOSTON and LAUSANNE, Switzerland, Dec. 29, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong and Chief Financial Officer Ross Muken, will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. The virtual presentation will begin at 8:15 a.m. ET/2:15 p.m. CET on Tuesday, January 11, 2022 and will be available live and archived on SOPHiAGENETICS.COM, in the Investor Relations section. About SOPH |